Compare Abbott Laboratories (ABT) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Linde PLC — how do they compare? Abbott Laboratories trades at $109.65 (market cap $187.95B), while Linde PLC trades at $490.21 (market cap $227.01B). The key difference: Linde PLC is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | LIN | |
|---|---|---|
Market Cap | $187.95B | $227.01B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $546.64 |
52-Week Low | $82.57 | $389.38 |
Enterprise Value | $214.96B | $250.13B |
Dividend Yield | 2.32% | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.
Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.
Linde (LIN) trades at $490.53, up 0.11% on the day, with a bearish technical signal despite strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.50 surpassing expectations. Revenue grew to $34.0B in 2025, with a net income margin of 20.43%. Analysts maintain a strong buy consensus with a $553.60 price target, highlighting robust profitability and dividend growth.
Outlook remains positive due to earnings momentum and sustainability leadership, but risks include elevated valuation multiples and rising debt-to-asset ratio. The stock offers steady income with a $1.60 dividend, yet technical weakness near support at $489 warrants caution for near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
